JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ustekinumab 6 mg/mL

First Posted Date: 2019-07-24

Last Posted Date: 2021-01-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 60

Registration Number: NCT04030533

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis
Eczema

Interventions: Drug: Bermekimab Monoclonal Antibody
Drug: Placebo

First Posted Date: 2019-07-16

Last Posted Date: 2023-09-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 87

Registration Number: NCT04021862

Locations: 🇺🇸
Doral Medical Research, Doral, Florida, United States
🇺🇸
Florida International Medical Research, Miami, Florida, United States
🇺🇸
Dawes Fretzin Clinical Research Group, Indianapolis, Indiana, United States

and more 14 locations

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa
Acne Inversa
Suppurative Hidradenitis

Interventions: Drug: placebo
Drug: bermekimab

First Posted Date: 2019-07-15

Last Posted Date: 2023-07-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 153

Registration Number: NCT04019041

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
P&S Research, LLC, Miami, Florida, United States
🇺🇸
Dawes Fretzin Clinical Research Group, Indianapolis, Indiana, United States

and more 29 locations

A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Drug: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)

First Posted Date: 2019-07-12

Last Posted Date: 2020-02-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 68

Registration Number: NCT04017195

Locations: 🇧🇪
SGS Belgium NV, Antwerpen, Belgium
🇩🇪
Charite - Universitatsmedizin Berlin (CCM), Berlin, Germany
🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

Phase 2

Completed

Conditions: HIV

Interventions: Drug: Rilpivirine
Drug: ARV Background Regimen

First Posted Date: 2019-07-09

Last Posted Date: 2024-05-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 26

Registration Number: NCT04012931

Locations: 🇪🇸
Hosp. Univ. La Paz, Madrid, Spain
🇿🇦
Josha Research, Bloemfontein, South Africa
🇹🇭
Siriraj Hospital Mahidol University, Bangkok, Thailand

and more 11 locations

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Phase 1

Completed

Conditions: Neoplasms
Colorectal Cancer
Advanced Solid Tumors
Non-small Cell Lung Cancer

Interventions: Drug: JNJ-74699157

First Posted Date: 2019-07-05

Last Posted Date: 2020-11-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10

Registration Number: NCT04006301

Locations: 🇺🇸
H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States
🇫🇷
Centre Leon Bérard, Lyon Cedex 8, France
🇫🇷
Hopital de la Timone, Marseille, France

and more 4 locations

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Completed

Conditions: Stroke

Interventions: Drug: Atypical Antipsychotics
Drug: Typical Antipsychotics
Drug: Haloperidol

First Posted Date: 2019-07-01

Last Posted Date: 2019-08-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1234412

Registration Number: NCT04002700

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-26366821
Drug: Placebo

First Posted Date: 2019-06-19

Last Posted Date: 2020-04-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT03990519

Locations: 🇺🇸
Harbor Hospital, Baltimore, Maryland, United States

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Completed

Conditions: Urothelial Cancer
Receptors, Fibroblast Growth Factor

Interventions: Other: Archival Tumor Tissue Sample

First Posted Date: 2019-05-20

Last Posted Date: 2023-02-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 3679

Registration Number: NCT03955913

Locations: 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇦🇷
Hospital Privado de Cordoba, Cordoba, Argentina

and more 196 locations

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64417184 600 (Oral Tablet Formulation)
Drug: JNJ-64417184 (Oral Suspension Formulation)

First Posted Date: 2019-05-16

Last Posted Date: 2020-05-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT03952507

Locations: 🇺🇸
PRA Health Sciences Salt Lake City Clinic, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy